NASDAQ: CYCN
Cyclerion Therapeutics Inc Stock Ownership - Who owns Cyclerion Therapeutics?

Insider buying vs selling

Have Cyclerion Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Peter M. HechtDirector2025-03-25181,818$2.75
$500.00kBuy
Michael J. 1. HigginsDirector2025-03-259,090$2.75
$25.00kBuy

1 of 1

CYCN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CYCN insiders and whales buy or sell their stock.

CYCN Shareholders

What type of owners hold Cyclerion Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Terrance McGuire19.65%771,191$1.03MInsider
Amy W. Schulman16.14%633,625$849.06kInsider
Peter M. Hecht14.26%559,760$750.08kInsider
Andreas Busch6.49%254,704$341.30kInsider
Mark G. Currie6.41%251,648$337.21kInsider
Siren LLC2.95%115,603$154.91kInstitution
Regina Margaret Graul2.56%100,303$134.41kInsider
William Huyett1.72%67,590$90.57kInsider
Geode Capital Management LLC1.10%43,302$58.02kInstitution
Christopher I. Wright1.09%42,728$57.26kInsider

1 of 3

CYCN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CYCN7.55%72.50%Net Buying
CDIO1.68%98.32%
VIVS0.60%99.40%Net Selling
XBIO5.33%94.67%
BGMS0.67%99.33%Net Selling

Cyclerion Therapeutics Stock Ownership FAQ

Who owns Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ: CYCN) is owned by 7.55% institutional shareholders, 72.50% Cyclerion Therapeutics insiders, and 19.96% retail investors. Terrance McGuire is the largest individual Cyclerion Therapeutics shareholder, owning 771,191.00 shares representing 19.65% of the company. Terrance McGuire's Cyclerion Therapeutics shares are currently valued at $1.03M.

If you're new to stock investing, here's how to buy Cyclerion Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.